Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target The firm believes the market may incorrectly written off micvotabart pelidotin, a first-in-concept non-internalizing antibody-drug conjugate against the novel target extra-domain B splice variant of fibronectin in the tumor stroma. The analyst thinks Pyxis may have a viable development path for micvotabart.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology initiated with a Buy at Guggenheim
- Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
- Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position
- Pyxis Oncology Reports Q2 2025 Financial Results
- Pyxis Oncology reports Q2 EPS (30c), consensus (35c)